Intraperitoneal distribution imaging in ovarian cancer patients

Internal Medicine Journal

Volumn 41, Issue 2, 2011, Pages 167-171

  Dawson, S J ^a   Hicks, R J ^b   Johnston, V ^b   Allen, D ^c   Jobling, T ^d   Quinn, M ^e   Rischin, D ^a  

^a Department of Haematology and Medical Oncology ^*  (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c MERCY HOSPITAL FOR WOMEN   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Cancer; Distribution; Imaging; Intraperitoneal; Ovarian

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMFG1 IN 111; MONOCLONAL ANTIBODY HMFG1 Y 90; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; IMAGING; OVARY CANCER; PERITONEAL FLUID; PRIORITY JOURNAL; SCINTIGRAPHY;

ANTINEOPLASTIC AGENTS; ASCITIC FLUID; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; OVARIAN NEOPLASMS;

EID: 79952015198     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.02112.x     Document Type: Article

References (23)

1. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA etal. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5.
2. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S etal. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
3. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF etal. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-7.
4. National Cancer Institute. Clinical announcement: intraperitoneal chemotherapy for ovarian cancer. 2006 Jan 4 [cited 2009 Nov]. Available from URL:
5. Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW etal. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007; 109: 692-702.
6. Marth C, Walker JL, Barakat RR, Casado A, Gadducci A, Miller B etal. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 2007; 109: 645-9.
7. Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol 2006; 24: 4531-3.
8. Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 2006; 24: 4528-30.
9. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89: 480-7.
10. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001; 61: 1057-65.
11. Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L etal. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 2001; 81: 77-81.
12. Muggia FM, LePoidevin E, Jeffers S, Russell C, Boswell W, Morrow CP etal. Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography. Ann Oncol 1992; 3: 149-54.
13. Yoonessi M, Abdel-Dayem HM, Shalaby OF. The use of scintigraphic and contrast peritoneography in gynecologic malignancies. Diagn Gynecol Obstet 1982; 4: 75-8.
14. de Forni M, Boneu A, Otal P, Martel P, Shubinski R, Bugat R etal. Anatomic changes in the abdominal cavity during intraperitoneal chemotherapy: prospective study using scintigraphic peritoneography. Bull Cancer 1993; 80: 345-50.
15. Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I etal. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003; 13(Suppl 2): 196-203.
16. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD etal. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 2849-55.
17. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS etal. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin - a gynecologic oncology group study. J Clin Oncol 2003; 21: 4350-5.
18. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT etal. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006; 24: 571-8.
19. Oei AL, Massuger LF, Oyen WJ. Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer. Cancer Biother Radiopharm 2007; 22: 508-14.
20. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006; 24: 988-94.
21. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA etal. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006; 100: 27-32.
22. Brandes JC, Packard WJ, Watters SK, Fritsche C. Optimization of dialysate flow and mass transfer during automated peritoneal dialysis. Am J Kidney Dis 1995; 25: 603-10.
23. Keshaviah P, Emerson PF, Vonesh EF, Brandes JC. Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis. J Am Soc Nephrol 1994; 4: 1820-6.